Premium
First year critical in monitoring weight in patients on antipsychotics
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30663
Subject(s) - aripiprazole , ziprasidone , quetiapine , neuropsychopharmacology , medicine , body mass index , antipsychotic , psychiatry , weight gain , body weight , pediatrics , schizophrenia (object oriented programming)
Most increases in weight that occurred in patients with first‐episode psychosis who received either aripiprazole, quetiapine, or ziprasidone were seen within the first year of treatment, a 3‐year prospective study has found. A comparison of the medication treatments concluded that patients receiving ziprasidone experienced smaller gains in weight and body mass index (BMI) than patients receiving aripiprazole. Study results were published in the October 2020 issue of European Neuropsychopharmacology .